Recent Updates on mRNA Vaccines

Sydow, Emily; Mustafa, Abu Salim; Hanif, Asma; Tunio, Javed; Hanif, Sajid

doi:10.3390/vaccines10081209

Search citation statements

Order By: Relevance

Paper Sections

Select...

Comparison Of Mrna Vs Peptide Vaccines1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…mRNA-and peptide-based cancer vaccines constitute the major forms of design to produce vaccines useful for cancer immunotherapies [28,29], and several clinical trials have been conducted with such formulations [30][31][32]. These clinical trials are classified as mRNAor peptide-based vaccinations.…”

Section: Comparison Of Mrna Vs Peptide Vaccinesmentioning

confidence: 99%

Recent Advances in Cancer Immunotherapy with a Focus on FDA-Approved Vaccines and Neoantigen-Based Vaccines

Hargrave,

Mustafa,

Hanif

et al. 2023

Vaccines

Self Cite

View full text Add to dashboard Cite

Cancer immunotherapies refer to the concept of retraining the immune system to target malignant cells. Multiple immunotherapeutic options exist including immune modulating antibodies, immune stimulating cytokines, chimeric antigen receptor T cell therapy, and vaccines. Overall, this field has advanced rapidly as knowledge of the tumor microenvironment, immunological pathways, and biotechnology expands. Specifically, advancements in neoantigen identification, characterization, and formulation into a vaccine show promise. This review is focused on previously United States Food and Drug Administration-approved cancer therapeutic vaccines and neoantigen-based vaccine developments along with the associated relevant clinical trials.

show abstract